Skip to main content
. Author manuscript; available in PMC: 2021 Dec 1.
Published in final edited form as: J Allergy Clin Immunol. 2020 Apr 15;146(6):1406–1418.e7. doi: 10.1016/j.jaci.2020.03.032

Figure 1. TSLP mediates acute eosinophilic airway inflammation.

Figure 1.

(a) Experimental design. WT and TSLPR deficient mice were treated intranasally with PBS, TSLP, OVA, or TSLP/OVA on d0, d3, and d6. On d7, the lungs of mice were harvested to evaluate airway inflammation by (b) eosinophilia (n=4–7), (c) lung histology (PAS staining), (d) mRNA expression of inflammatory mediators, Il4, Il13, Ccl24, Muc5ac, and Ifng (n=2–3), and (e) percentage and numbers of IL-13-producing effector CD4 T cells (n=3–4). Data are representative or combined of at least two independent experiments. Error bars represent SEM. * p<0.05, ** p<0.01***, p<0.001, ****p<0.0001. p-value by one-way ANOVA adjusted with Tukey’s multiple comparison test (b) or student’s two-tailed t test (d)(e).